Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3788906 | 0.86 | ADORA2A (0.43) | ADORA2AADORA3ADORA2BCYP2C19EGFR | |
| SCHEMBL3790046 | 0.81 | DYRK1A (0.45) | ADORA2AADORA2BADORA1 | |
| SCHEMBL3787423 | 0.80 | AAK1 (0.38) | ADORA2BEGFR | |
| SCHEMBL996391 | 0.79 | MAPT (0.40) | ADORA2ACYP2C19EGFR | |
| SCHEMBL3790043 | 0.77 | ADORA2B (0.43) | ADORA2AADORA2BCYP2C19ADORA1 | |
| SCHEMBL3791247 | 0.75 | ALDH1A1 (0.36) | — | |
| SCHEMBL14547056 | 0.73 | ADORA2A (0.41) | ADORA2AADORA3ADORA2BCYP2C19ADORA1 | |
| SCHEMBL994806 | 0.70 | DHFR (0.38) | ADORA2AEGFRADORA1 | |
| SCHEMBL3792241 | 0.68 | ADORA2A (0.46) | ADORA2AADORA3ADORA2BCYP2C19ADORA1 | |
| SCHEMBL3787415 | 0.67 | ADORA2B (0.42) | ADORA2AADORA2BEGFRADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855202-B2 | Imidazopyridine derivatives as A2B adenosine receptor antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-12-21 | — | — | US | disclosed |
| US-20080275038-A1 | Imidazopyridine Derivatives as A2b Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275038-A1 | Imidazopyridine Derivatives as A2b Adenosine Receptor Antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA3 4/4885ADORA2B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.